Antibodies that target α4β7 (LPAM1) are commonly used to treat IBD [25], and usually also favored due to their gut-specific effects; they also have a reported higher efficacy compared to anti-TNF therapy, specifically for moderate–severe UC [29]. The gene discussed is TNF; the disease is inflammatory bowel disease.